FDA has approved a generic drug under Application #ANDA211255 manufactured by ACTAVIS LABS FL, removing any potential generic competition for the subject product. The approval is expected to establish a new pricing standard, allowing ACTAVIS LABS FL to capitalize on the market conditions for the branded drug until patents expire.